Palisade Bio, Inc.
PALI- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001357459
In the last 90 days, Palisade Bio, Inc. insiders filed 3 open-market purchases and 2 sales; 124 institutions reported holding it in 13F filings for Q2 2026, worth $362.4M in total; no superinvestor holds it.
Q4 2024 vs. Q3 2024
How the institutions holding Palisade Bio, Inc. changed between Q3 2024 and Q4 2024.
All holders in Q4 2024All holders in Q3 2024
| Measure | Q3 2024 | Q4 2024 | Change |
|---|---|---|---|
| Holders | 9 | 10 | +1 |
| Shares | 97.9K | 235.0K | +137.1K (+140.1%) |
| Value | $347.4K | $387.7K | +$40.3K (+11.6%) |
New holders (2)
Institutions that held Palisade Bio, Inc. at the end of Q4 2024 but not at the end of Q3 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Cetera Investment Advisers | 70,006 | $115.5K | 0.00% |
| Geode Capital Management, LLC | 10,052 | $16.6K | 0.00% |
Sold out (1)
Institutions that held Palisade Bio, Inc. at the end of Q3 2024 and filed for Q4 2024 without it.
| Institution | Shares, Q3 2024 | Value, Q3 2024 |
|---|---|---|
| JPMorgan Chase & Co | 8,200 | $29.1K |